Standout Papers

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory A... 2017 2026 2020 2023 447
  1. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma (2017)
    Frederick L. Locke, Sattva S. Neelapu et al. Molecular Therapy

Immediate Impact

1 by Nobel laureates 10 from Science/Nature 66 standout
Sub-graph 1 of 20

Citing Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
2024 Standout
2 intermediate papers

Works of Jeff Aycock being referenced

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
2017 Standout

Author Peers

Author Last Decade Papers Cites
Jeff Aycock 573 141 93 168 155 24 607
Meg Elias 520 127 87 149 149 15 551
Christina A. Bachmeier 496 114 136 117 123 27 571
Fenlu Zhu 464 142 42 119 174 20 567
Birju Mehta 588 225 59 229 171 17 653
Elizabeth Halton 536 123 46 186 116 29 584
Mohamed-Reda Benmebarek 557 240 24 142 198 17 634
Yueh-wei Shen 445 206 24 113 186 13 591
Simon Thomas 651 192 34 213 271 27 728
Agne Taraseviciute 474 92 18 150 136 15 630
Chenggong Li 369 99 44 115 240 35 531

All Works

Loading papers...

Rankless by CCL
2026